TRCT
LUNG icon

Tower Research Capital (TRC)’s Pulmonx LUNG Stock Holding History

Tower Research Capital (TRC)’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06K Sell
2,352
-9,050
-79% -$12.5K ﹤0.01% 4577
2026
Q1 		$14.7K Buy
11,402
+6,718
+143% +$11.1K ﹤0.01% 3690
2025
Q4 		$10.4K Sell
4,684
-10,639
-69% -$20K ﹤0.01% 3791
2025
Q3 		$24.8K Buy
15,323
+9,054
+144% +$18.9K ﹤0.01% 3105
2025
Q2 		$16.2K Buy
6,269
+1,889
+43% +$7.45K ﹤0.01% 3790
2025
Q1 		$29.5K Sell
4,380
-2,053
-32% -$14.5K ﹤0.01% 2626
2024
Q4 		$43.7K Buy
6,433
+572
+10% +$3.77K ﹤0.01% 2638
2024
Q3 		$48.6K Sell
5,861
-1,691
-22% -$12.2K ﹤0.01% 2735
2024
Q2 		$47.9K Buy
7,552
+6,884
+1,031% +$52.9K ﹤0.01% 3135
2024
Q1 		$6.19K Sell
668
-10,242
-94% -$120K ﹤0.01% 4413
2023
Q4 		$139K Sell
10,910
-846
-7% -$8.81K ﹤0.01% 2377
2023
Q3 		$121K Buy
11,756
+10,770
+1,092% +$125K ﹤0.01% 1839
2023
Q2 		$12.9K Sell
986
-81
-8% -$991 ﹤0.01% 3820
2023
Q1 		$12K Sell
1,067
-19,140
-95% -$189K ﹤0.01% 4094
2022
Q4 		$170K Buy
20,207
+17,929
+787% +$171K 0.01% 1420
2022
Q3 		$38K Sell
2,278
-2,974
-57% -$54.8K ﹤0.01% 3403
2022
Q2 		$77K Sell
5,252
-4,639
-47% -$95.6K ﹤0.01% 2498
2022
Q1 		$245K Buy
9,891
+7,675
+346% +$198K ﹤0.01% 1586
2021
Q4 		$71K Buy
2,216
+1,295
+141% +$47.3K ﹤0.01% 2482
2021
Q3 		$34K Sell
921
-4,154
-82% -$163K ﹤0.01% 3264
2021
Q2 		$224K Buy
5,075
+2,840
+127% +$124K 0.01% 1838
2021
Q1 		$102K Buy
2,235
+1,994
+827% +$114K ﹤0.01% 2567
2020
Q4 		$17K Buy
+241
New +$11.8K ﹤0.01% 3968

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Tower Research Capital (TRC)'s LUNG Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Pulmonx (LUNG) stake by 79% in Q2 2026, selling an estimated $12.5K and leaving 2,352 shares worth $3.06K. The position accounts for ﹤0.01% of the portfolio, ranked #4577.

Tower Research Capital (TRC) first reported a position in LUNG in Q4 2020 and has held it in 23 quarters since. The position peaked at $245K in Q1 2022. 108 funds tracked by Wall St. Rank hold LUNG as of Q2 2026.

  • Tower Research Capital (TRC) held 2,352 shares of Pulmonx worth $3.06K as of Q2 2026.
  • Tower Research Capital (TRC) sold 9,050 Pulmonx shares in Q2 2026, an estimated $12.5K.
  • Pulmonx made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4577 holding.
  • Tower Research Capital (TRC) first reported a position in Pulmonx in Q4 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Pulmonx position peaked at $245K in Q1 2022.
  • 108 funds tracked by Wall St. Rank held Pulmonx as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.